By Fineline Cube 
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) reported unaudited interim results for the six months ended June 30, 2025. Revenue reached approximately RMB 7.434 billion, a 14.3% increase year-on-year, while profit grew by 15.0% year-on-year to approximately RMB 3.135 billion. Revenue from innovative drugs and collaborative products grew by 22.1% year-on-year to RMB 6.145 billion, accounting for 82.7% of total revenue. R&D expenditure increased by 20.4% year-on-year to approximately RMB 1.441 billion.
Ameile’s Market Expansion
Revenue from oncology products, including the innovative drug Ameile (Aumolertinib Mesilate Tablets), reached approximately RMB 4.531 billion, or 60.9% of total revenue. As China’s first original third-generation EGFR-TKI drug, Ameile continues to expand its therapeutic potential in lung cancer treatment, with four indications approved in China. In May 2025, it was approved for treating adult patients with stage II to IIIB non-small cell lung cancer (NSCLC). In June 2025, Ameile, marketed as Aumseqa in the UK, received marketing authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).
Pipeline Momentum
Hansoh expanded its innovative drug pipeline with over 70 ongoing clinical trials, covering more than 40 drug candidates. Notable additions included phase 3 pivotal registration trials for HS-20093, a B7-H3-targeted ADC for bone and soft tissue sarcoma; HS-20089, a B7-H4-targeted ADC for ovarian cancer; and HS-20137, an IL-23p19 monoclonal antibody. Additionally, eight new drug candidates, including two ADCs, were approved for clinical trials, underscoring the company’s commitment to innovation.-Fineline Info & Tech